Company intelligence / Profile preview

Diablo Clinical Research

Walnut Creek, California, United Statesdiabloclinical.com ↗

Ownership: Private
Employees: ~29
Development stage: Commercial

Overview

Diablo Clinical Research has completed over a thousand Phase I–IV clinical trials as an independent single-site facility with particular strengths in endocrinology, cardiovascular, metabolic diseases, and medical devices. The site has contributed to pivotal studies in diabetes and obesity therapeutics including GLP‑1 analogs and combination therapies. It was acquired by Flourish Research in February 2025 to expand geographic reach and therapeutic expertise.

Therapeutic areas: EndocrinologyOphthalmology
Modalities: Small moleculeBiologicDevice
Industry: Contract Research Organization

Partnerships

Sponsors include major pharmaceutical companies developing metabolic/cardiovascular drugs/devicesalso works with CROs

Beyond the preview

Go deeper on Diablo Clinical Research.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Diablo Clinical Research.

Explore the full profile